```
 * * * * * * * * *   Welcome to STN International   * * * * * * * * * *
 * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:00:31 ON 09 FEB 2006

=> file reg
=> Uploading C:\Program Files\Stnexp\Queries\10509396.str

L1    ·  STRUCTURE UPLOADED

=> dis l1
L1-HAS NO ANSWERS
L1              STR
```




```
Structure attributes must be viewed using STN Express query preparation.


=> s l1 sam
L2            9 SEA SSS SAM L1

=> s l1 full
L3          331 SEA SSS FUL L1

=> file caplus
=> s l3
L4           10 L3

=> s l4 and pd<feb 2002
      22507607 PD<FEB 2002
                  (PD<20020200)
L5            2 L4 AND PD<FEB 2002

=> dis l5 1-2 bib abs hitstr

L5   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2006 ACS on STN
AN   1997:549356  CAPLUS
DN   127:152950
TI   Multiple unit effervescent dosage forms comprising proton pump inhibitor
IN   Lundberg, Per Johan
PA   Astra Aktiebolag, Swed.; Lundberg, Per Johan
SO   PCT Int. Appl., 56 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
```

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 9725030	A1	19970717	WO 1996-SE1738	19961220	<--
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN					
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
	SE 9600073	A	19970709	SE 1996-73	19960108	<--
	SE 512835	C2	20000522			
	CA 2214027	AA	19970717	CA 1996-2214027	19961220	<--
	AU 9713242	A1	19970801	AU 1997-13242	19961220	<--
	AU 712325	B2	19991104			
	BR 9607367	A	19971230	BR 1996-7367	19961220	<--
	EP 814783	A1	19980107	EP 1996-944727	19961220	<--
	EP 814783	B1	20031008			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
	CN 1183716	A	19980603	CN 1996-193763	19961220	<--
	IL 121653	A1	20010808	IL 1996-121653	19961220	<--
	AT 251451	E	20031015	AT 1996-944727	19961220	
	PT 814783	T	20040227	PT 1996-944727	19961220	
	ES 2208775	T3	20040616	ES 1996-944727	19961220	
	ZA 9610939	A	19970708	ZA 1996-10939	19961230	<--
	US 6132770	A	20001017	US 1997-793077	19970213	<--
	NO 9704051	A	19971015	NO 1997-4051	19970903	<--
	NO 319999	B1	20051010			
PRAI	SE 1996-73	A	19960108			
	WO 1996-SE1738	W	19961220			

OS MARPAT 127:152950

AB A new tabletted multiple unit effervescent dosage form containing an acid susceptible proton pump inhibitor in the form of the racemate, an alkaline salt thereof or one of its single enantiomers or an alkaline salt thereof, and effervescent tablet constituents are claimed (Markush structure given). The proton pump inhibitor is preferably omeprazole or an alkaline salt thereof, or S-omeprazole or an alkaline salt thereof. Pellets comprising non-pareil cores 400, lansoprazole 400, hydroxypropyl Me cellulose 80, sodium lauryl sulfate 3, and water 1360 g were prepared The above pellets (100 g) were coated with a solution comprising hydroxypropyl Me cellulose 9, polyethylene glycol-6000 1, talc 18, 95% ethanol 250, and water 250 g. The above sub-coated pellets were enteric coated with a solution comprising hydroxypropyl Me cellulose phthalate 40, acetyltributyl citrate 8, cetanol 2, 95% ethanol 162, and acetone 378 g. The enteric-coated pellets were mixed with effervescent granules (preparation given) and compressed into tablets.

IT **193335-90-9**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(multiple unit effervescent dosage forms comprising proton pump inhibitor)

RN 193335-90-9 CAPLUS

CN Ethanone, 2-(4-methoxy-3,5-dimethyl-2-pyridinyl)-1-(5-methyl-1H-imidazo[4,5-b]pyridin-2-yl)- (9CI) (CA INDEX NAME)



L5 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1995:665761 CAPLUS
DN 123:340706
TI Synthesis and bioactivity of substituted adenines and adenosines
AU Deng, H. F.; Jiang, Y. Z.; Zhao, Z. Z.
CS Inst. Mater. Med., Chin. Acad. Med. Sci., Beijing, 100050, Peop. Rep. China
SO Yaoxue Xuebao (**1995**), 30(5), 347-56
CODEN: YHHPAL; ISSN: 0513-4870
PB Chinese Academy of Medical Sciences, Institute of Materia Media
DT Journal
LA Chinese
GI



I

AB Title compds. e.g., I (R = H, 2-pyridylmethyl, 3-methyl-2-pyridylmethyl, 3,5-dimethyl-2-pyridylmethyl, 3,5-dimethyl-4-methoxy-2-pyridylmethyl; R1 = PhCH2, ribosyl, 2-pyridylmethyl, 3-methyl-2-pyridylmethyl, 3,5-dimethyl-2-pyridylmethyl, 3,5-dimethyl-4-methoxy-2-pyridylmethyl, 5-acetoxy-2-pyridylmethyl) were prepared using adenine and adenosine as starting materials. The structures of these compds. were identified with MS, 1HNMR and UV spectra. All adenosine derivs. and some adenine derivs. synthesized were studied for adenosine receptor activity. I (R = 2-pyridylmethyl, R1 = ribosyl) was 33 times more active than adenosine.
IT **170451-99-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis and bioactivity of substituted adenines and adenosines)
RN 170451-99-7 CAPLUS
CN 9H-Purin-6-amine, 9-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]- (9CI) (CA INDEX NAME)



IT **170452-03-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis and bioactivity of substituted adenines and adenosines)
RN 170452-03-6 CAPLUS
CN 3H-Purin-6-amine, 3-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]- (9CI) (CA INDEX NAME)



=> s l4 not l5
L6 8 L4 NOT L5

=> dis l6 1-8 bib abs

L6 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:588961 CAPLUS
DN 143:115536
TI A preparation of (aminopyridinylethyl)imidazolopyridine derivatives, useful as inductible NO-synthase inhibitors
IN Boer, Rainer; Marx, Degenhard; Ulrich, Wolf-Ruediger; Eltze, Manfrid; Nave, Ruediger; Strub, Andreas; Graedler, Ulrich; Fuchss, Thomas
PA Altana Pharma A.-G., Germany
SO PCT Int. Appl., 63 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005061496	A1	20050707	WO 2004-EP52373	20040930

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

PRAI EP 2003-22040 A 20031001
OS MARPAT 143:115536
GI



I



II

AB The invention relates to a preparation of (aminopyridinylethyl)imidazolopyridin e derivs. of formula I [wherein: R1 is H or alkyl; R2 is H, halogen, NH2, (cyclo)alkyl, or CF3, etc.; R3 is H, halogen, alkyl, or alkoxyl R4 is alkyl or alkoxy], useful as antiinflammatory agents (inductible NO-synthase inhibitors). For instance, (aminopyridinylethyl)imidazolopyri dine derivative II was prepared via condensation of 4-methyl-2-(tritylamino)picolinaldehyde with [3H-imidazo[4,5-b]pyridin-2-ylmethyl]triphenylphosphonium chloride and subsequent reduction of the obtained intermediate. The invention compds. were tested for NO-synthase activity [-logIC50(mol/L) values range from 6.58 to 8.15].

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:300447 CAPLUS
DN 142:373838
TI Preparation of imidazopyridine derivatives as inducible NO-synthase inhibitors

IN Fuchss, Thomas; Martin, Thomas; Boer, Rainer; Strub, Andreas; Eltze, Manfrid; Lehner, Martin; Ulrich, Wolf-Ruediger
PA Altana Pharma A.-G., Germany
SO PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005030771	A1	20050407	WO 2004-EP52378	20040930

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI EP 2003-22053 A 20031001
OS MARPAT 142:373838
GI



I



II

AB Title compds. I [R1 = H, alkyl; R2 = H, alkyl; R3 = H, halo; R4 = H, halo, alkyl, alkoxy; R5 = alkyl; A = alkylene] and their resp. pharmaceutically acceptable salts, are prepared and disclosed as inducible no-synthase inhibitors. Thus, e.g., II was prepared via Suzuki coupling of 2-[2-(4-methoxypyridin-2-yl)ethyl]-6-iodo-3H-imidazo[4,5-b]pyridine (preparation given) with N,N-dimethyl-4-bromobenzenesulfonamide. The activity of I towards inducible NO-synthase was evaluated in inhibition assays and

revealed -logIC50 values in the range of 7.45 up to 7.86 mol/L. I as inducible NO-synthase inhibitors should prove useful in the treatment of acute and chronic inflammatory diseases.

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:300446 CAPLUS
DN 142:373837
TI Preparation of imidazopyridine derivatives as inducible NO-synthase inhibitors
IN Fuchss, Thomas; Martin, Thomas; Boer, Rainer; Strub, Andreas; Eltze, Manfrid; Lehner, Martin; Ulrich, Wolf-Ruediger
PA Altana Pharma A.-G., Germany
SO PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005030770	A1	20050407	WO 2004-EP52377	20040930
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI EP 2003-22046	A	20031001		

OS MARPAT 142:373837
GI



I



II

AB Title compds. I [R1 = H, alkyl, cycloalkyl, etc.; R2 = H, alkoxyalkyl, hydroxyalkyl, etc.; R3 = alkyl, CF3, completely or predominantly F-substituted alkoxy, etc.; R1 and R2 together = (un)saturated-, (un)substituted-nitrogen heterocycle; R4 = H, halo, alkyl, alkoxy; R5 = alkyl; A = alkylene] and their resp. pharmaceutically acceptable salts, are prepared and disclosed as inducible no-synthase inhibitors. Thus, e.g., II was prepared via Suzuki coupling of 2-[2-(4-methoxypyridin-2-yl)ethyl]-6-iodo-3H-imidazo[4,5-b]pyridine (preparation given) with 1-(4-bromo-benzenesulfonyl)-4-methyl-piperazine. The activity of I towards inducible NO-synthase was evaluated in inhibition assays and revealed -logIC50 values in the range of 6.51 up to 7.89 mol/L. I as inducible NO-synthase inhibitors should prove useful in the treatment of acute and chronic inflammatory diseases.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:300445 CAPLUS
DN 142:373836
TI Preparation of imidazopyridine derivatives as inducible NO-synthase inhibitors
IN Fuchss, Thomas; Martin, Thomas; Boer, Rainer; Strub, Andreas; Eltze, Manfrid; Lehner, Martin; Marx, Degenhard; Ulrich, Wolf-Ruediger
PA Altana Pharma A.-G., Germany
SO PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005030769	A1	20050407	WO 2004-EP52376	20040930

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI EP 2003-22064 A 20031001
OS MARPAT 142:373836
GI



I



II

AB Title compds. I [R1 = alkoxy; A = alkylene; R2 = H, halo, alkyl, alkoxy; Het = (un)substituted monocyclic or fused 5-10 membered (un)saturated heteroaryl containing 1-3 heteroatoms selected from N, O, and S] and their resp. pharmaceutically acceptable salts, are prepared and disclosed as inducible no-synthase inhibitors. Thus, e.g., II was prepared via Suzuki coupling of 2-[2-(4-methoxypyridin-2-yl)ethyl]-6-iodo-3H-imidazo[4,5-b]pyridine (preparation given) with 2-furanylboronic acid. The activity of I towards inducible NO-synthase was evaluated in inhibition assays and revealed -logIC50 values from 6.61 up to 7.61 mol/L. I as inducible NO-synthase inhibitors should prove useful in the treatment of acute and chronic inflammatory diseases.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:300444 CAPLUS
DN 142:373835
TI Preparation of imidazopyridine derivatives as inducible NO-synthase inhibitors
IN Boer, Rainer; Ulrich, Wolf-Ruediger; Eltze, Manfrid; Marx, Degenhard; Graedler, Ulrich; Fuchss, Thomas
PA Altana Pharma A.-G., Germany

SO PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005030768	A1	20050407	WO 2004-EP52370	20040930

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI EP 2003-22042 A 20031001
OS MARPAT 142:373835
GI



I



II

AB Title compds. I [R1 = H, alkyl; R2 = H, halo, OH, etc.; R3 = H, halo, alkyl, alkoxy; R4 = alkyl; R5 = alkyl] and their resp. pharmaceutically acceptable salts, are prepared and disclosed as inducible no-synthase inhibitors. Thus, e.g., II was prepared via Wittig reaction of triphenyl-{1-(3H-imidazo[4,5-b]pyridin-2-yl)-propyl}-phosphonium chloride (preparation given) with 4-methoxypyridine-2-carboxaldehyde and subsequent hydrogenation. The activity of II towards inducible NO-synthase was evaluated in an inhibition assay and revealed a -logIC50 value of 7.15 mol/L. I as inducible NO-synthase inhibitors should prove useful in the treatment of acute and chronic inflammatory diseases.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:283463 CAPLUS
DN 142:336389
TI Preparation of novel heterocyclic compounds such as aminopurines, aminopyrrolopyrimidines, aminopyrazolopyrimidines and aminotriazolopyrimidines as HSP90-inhibitors
IN Kasibhatla, Srinivas R.; Boehm, Marcus F.; Hong, Kevin D.; Biamonte, Marco A.; Shi, Jiandong; Le Brazidec, Jean-yves; Zhang, Lin; Hurst, David
PA Conforma Therapeutics Corporation, USA
SO PCT Int. Appl., 506 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005028434	A2	20050331	WO 2004-US31248	20040920
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2005107343	A1	20050519	US 2004-945851	20040920
	US 2005113339	A1	20050526	US 2004-946628	20040920
	US 2005113340	A1	20050526	US 2004-946645	20040920
	US 2005119282	A1	20050602	US 2004-946637	20040920
PRAI	US 2003-504135P	P	20030918		
	US 2004-591467P	P	20040726		

OS MARPAT 142:336389
GI



I



II

AB Novel heterocyclic compds. (shown as I; other Markush structures are given in the claims; variables defined below; e.g. [4-chloro-7-(4-methoxy-3,5-dimethylpyridin-2-ylmethyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl]amine (shown as II)) are described and demonstrated to have utility as Heat Shock

Protein 90 (HSP90) inhibiting agents. Method of synthesis and use of such compds. are also described. For I: X1 and X2 are N or -CR6; X3 is N or -CR3 (R3 is H, OH, a keto tautomer, -OR8, -CN, halogen, lower alkyl, or -C(O)R9); X4 is N or a group CR6 when X3 is N, and X4 is -CR6R7 when X3 is -CR3; R1 is halogen, -OR8, -SR8, or lower alkyl; R2 is -NR8R10; R4 is -(CH2)n- where n = 0-3, -C(O), -C(S), -SO2-, or -SO2N-; and R5 is alkyl, aryl, heteroaryl, alicyclic, heterocyclic, all optionally bi- or tricyclic, and (un)substituted with H, halogen, lower alkyl, lower alkenyl, lower alkynyl, lower aryl, lower alicyclic, aralkyl, aryloxyalkyl, alkoxyalkyl, perhaloalkyl, perhaloalkyloxy, perhaloacyl, -N3, -SR8, -OR8, -CN, -CO2R9, -NO2, or -NR8R10; with provisos. Methods of preparation are claimed and >200 example prepns. are included. For example, II was prepared by alkylation of (4-chloro-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amine with 2-chloromethyl-4-methoxy-3,5-dimethylpyridine hydrochloride.

L6 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:777790 CAPLUS
DN 139:292156
TI Preparation of alkoxypyridines as inducible nitric oxide synthase (iNOS) inhibitors
IN Boer, Rainer; Marx, Degenhard; Eltze, Manfrid; Klein, Thomas; Nave, Ruediger; Graedler, Ulrich; Fuchss, Thomas; Barsig, Johannes; Ulrich, Wolf-Ruediger
PA Altana Pharma A.-G., Germany
SO PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003080607	A1	20031002	WO 2003-EP3076	20030325
	W: AE, AL, AU, BA, BR, CA, CN, CO, CU, DZ, EC, GE, HR, ID, IL, IN, IS, JP, KR, LT, LV, MA, MK, MX, NO, NZ, PH, PL, SG, TN, UA, US, VN, YU, ZA, ZW				
	RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
	CA 2480385	AA	20031002	CA 2003-2480385	20030325
	AU 2003226706	A1	20031008	AU 2003-226706	20030325
	EP 1490366	A1	20041229	EP 2003-744851	20030325
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003008785	A	20050111	BR 2003-8785	20030325
	US 2005171125	A1	20050804	US 2003-509396	20030325
	JP 2005525388	T2	20050825	JP 2003-578361	20030325
	NO 2004004633	A	20041223	NO 2004-4633	20041027
PRAI	EP 2002-7049	A	20020327		
	WO 2003-EP3076	W	20030325		

OS MARPAT 139:292156
GI



I



II

AB Title compds. I [wherein R1 = alkoxy; A = alkylene; B = (un)substituted 3H-imidazo[4,5-b]pyridin-2-yl, 9H-purin-8-yl; their salts, N-oxides, and salts of the N-oxides] were prepared as inducible NO-synthase (iNOS) inhibitor for treatment of acute inflammatory diseases and chronic inflammatory diseases of peripheral organs and central nervous system (CNS). For example, II (m.p. = 116-117°) was prepared by cyclocondensation of Me 3-(4-methoxypyridin-2-yl)propionate (preparation given) with 2,3-diaminopyridine in the presence of polyphosphoric acid at 160° for 1 h. Selected invention compds. inhibited iNOS with -logIC50 (M) in the range of 7.03-7.55. Thus, I and their pharmaceutical compns. are useful for treating acute inflammatory diseases, chronic inflammatory diseases of peripheral organs and CNS and cancer (no data).
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:539534 CAPLUS
DN 137:109285
TI Preparation of triazolo[4,5-d]pyrimidines as purinergic receptor antagonists
IN Gillespie, Roger John; Lerpiniere, Joanne; Gaur, Suneel; Bamford, Samantha Jayne; Stratton, Gemma Caroline; Leonardi, Stefania; Weiss, Scott Murray
PA Vernalis Research Limited, UK
SO PCT Int. Appl., 157 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002055083	A1	20020718	WO 2002-GB91	20020110

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,

```
            CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
            BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     CA 2433453           AA    20020718    CA 2002-2433453        20020110
     EP 1392312           A1    20040303    EP 2002-729452         20020110
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
     CN 1496262           A     20040512    CN 2002-806303         20020110
     NZ 527248            A     20040528    NZ 2002-527248         20020110
     JP 2004517862        T2    20040617    JP 2002-555817         20020110
     BR 2002006559        A     20040622    BR 2002-6559           20020110
     ZA 2003005087        A     20040712    ZA 2003-5087           20020110
     NO 2003003146        A     20030909    NO 2003-3146           20030709
     US 2004097526        A1    20040520    US 2003-250942         20031008
PRAI GB 2001-624          A     20010110
     WO 2002-GB91         W     20020110
OS   MARPAT 137:109285
GI
```



I

AB The title compds. [I; R1 = H, alkyl, aryl, etc.; R2 = aryl attached via an unsatd. carbon; R3 = H, alkyl, COR5, CO2R7, CONR5R6, CONR4NR5R6, SO2R7; R4-R6 = H, alkyl, aryl; or NR5R6 = heterocyclyl; or where R4-R6 are in a CONR4NR5R6 group, R4 and R5 may be linked to form a heterocyclic group; R7 = alkyl, aryl], useful in the treatment or prevention of a disorder in which the blocking of purine receptors, particularly adenosine receptors and more particularly A2A receptors, may be beneficial, particularly wherein said disorder is a movement disorder such as Parkinson's disease or depression, cognitive or memory impairment, acute or chronic pain, ADHD or narcolepsy, or for neuroprotection, were prepared Thus, reacting 7-(2-furyl)-1H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine (preparation given) with 2-fluorobenzyl bromide in the presence of NaH in DMF afforded 22% I [R1 = NH2; R2 = 2-furyl; R3 = 2-FC6H4CH2] which showed Ki of 3 nM against A2A receptor binding.

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    35.01     202.60

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -7.50      -7.50

STN INTERNATIONAL LOGOFF AT 13:02:55 ON 09 FEB 2006
```

C:\Program Files\Stnexp\Queries\10509396.str





chain nodes :
7 8 10 11
ring nodes :
1 2 3 4 5 6
chain bonds :
4-7 6-10 7-8 10-11
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
4-7 7-8 10-11
exact bonds :
6-10
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 10:CLASS 11:Atom
Generic attributes :
11:
Number of Carbon Atoms : less than 7
Number of Hetero Atoms : 2 or more
Type of Ring System : Polycyclic

Element Count :
Node 11: Limited
N,N2